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See Article, pages 1049–1053Co-amoxiclav is a combination antibiotic containing amoxicillin
trihydrate, a b-lactam antibiotic, with the potent b-lactamase
inhibitor clavulanic acid. It is one of the most prescribed antibi-
otic worldwide both because of its large spectrum of action and
for its general good safety. Amongst the possible side-effects of
co-amoxiclav are diarrhea, vomiting, and thrush, which do not
usually require medical attention. It can also induce allergic reac-
tions and, as all antimicrobial agents, pseudomembranous colitis.
Lastly, co-amoxiclav is known to have caused drug-induced liver
injury (DILI) in some patients [1–3]. Although DILI is a very rare
event, co-amoxiclav is one of the most common causes of DILI
[2,3].
DILI is a rare idiosyncratic adverse drug reaction associated
with commonly used drugs, mostly non-steroidal anti-inﬂamma-
tory drugs, paracetamol, and antimicrobial agents [4,5]. Mainly
because of the lack of internationally accepted criteria for DILI,
data on the incidence of DILI cases are extremely variable [6,7].
It should be noted that half of the cases of acute liver failure
are due to drug hepatotoxicity [4,5]. Recent major methodologi-
cal and technological advances in many ﬁelds of basic science
(i.e. the use of animals with various gene knockouts [8]) have
contributed to a breakthrough in the understanding of the mech-
anisms underling DILI.
Based on the fact that a unique predisposition is required to
develop a DILI, over the last few years several research groups
have tried to understand the role of genetics in DILI [9]. However,
the literature on DILI contains large numbers of publications that
have attempted to identify the responsible genes by evaluating
small numbers of single nucleotide polymorphisms in one or
few speciﬁc candidate genes by means of case–control study
designs [9]. Unfortunately, as in many other complex conditions
(i.e. autoimmune diseases [10,11]), such approaches have led to
few insights into the genetic basis of DILI, mainly because of its
rarity and the consequent difﬁculty to ﬁnd large numbers of
affected individuals. A possible exception is the quite consistent
ﬁndings of an association between the co-amoxiclav-induced
liver injury and some human leukocyte antigen (HLA) alleles
[12–15]. Indeed, an association has been reported betweenJournal of Hepatology 20
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studies focused on this topic (Table 1) [12,13,15].
In the current issue of the Journal of Hepatology, Donaldson
et al. [14] conﬁrm the already known HLA association with
DRB1*15 and also provide novel relevant data. In particular, they
report a novel protective association with DRB1*07 within the
HLA region [14]. The major strength of this study is the typing
of the largest collection of DNA (n = 61) from patients with co-
amoxiclav-related DILI (Table 1), and the inclusion, for the ﬁrst
time, of a control group of patients exposed to co-amoxiclav
but showing no toxicity. We should note, however, that although
the authors must be commended for their enormous multicentric
effort in collecting DNA from this very rare condition, 61 cases is
a small series to be typed in a genetic association study. Further-
more, the results herein, similar to other gene descriptions in DILI
patients, do not include functional analysis.
The publication of the ﬁrst high-density genome-wide associ-
ation study (GWAS) in cases with DILI due to an antimicrobial
agent, ﬂucloxacillin [16], has now opened a new era in the ﬁeld
of DILI which will surely allow substantial advances in our mech-
anistic understanding of DILI [9]. It should be noted that this ﬁrst
GWAS identiﬁed HLA variants as risk factors for liver toxicity due
to ﬂucloxacillin. Although it has been suggested that genetic
associations for DILI are generally drug speciﬁc [9], the HLA class
I and II genes are emerging as major players in the predisposition
to most forms of DILI [9]. HLA genes play a crucial role in the host
immune response because they are involved in antigen presenta-
tion [17,18]. For this reason, the immunologic idiosyncrasy may
be mediated by the HLA system and DILI may be linked with cer-
tain HLA genes [9]. Unfortunately, since Donaldson et al. did not
perform a GWAS with their unique collection of DNA, their cur-
rent candidate gene study can only conﬁrm the role of HLA genes
in co-amoxiclav-related liver toxicity, but it cannot exclude that
other genes also have a role in the predisposition to this form
of DILI [14].
The main aim of genetic studies on DILI is their contribution in
aiding prediction in individual patients [19], in line with the rapid
advances in genetics-based personalized medicine. The issue is of
major clinical relevance and the expectation is very high [5].
However, because the current ﬁrst wave of GWAS allows for
the identiﬁcation of only rare genetic variants [11] and because10 vol. 53 j 993–994
Table 1. Reported HLA associations in co-amoxiclav-induced liver injury.
Years Country HLA 
investigated 
Significant association 
with 
Prevalence in  
ILIDvalcixoma-oc
(n)  
Prevalence in 
controls 
(n) 
Corrected 
p value 
[Ref.]
1999 Belgium A, B, DRB, 
DQB 
DRB1*1501 
DRB5*0101 
DQB1*0602  
57% (20/35) 
57% (20/35) 
57% (20/35) 
15% (9/60) 
15% (9/60) 
12% (7/60) 
<0.003 
<0.003 
<0.0005 
[12]  
2000 U.K. DRB, DQA, 
DQB, DPB 
DRB1*1501 67% (12/18) 20% (27/134) <0.0002 [13]  
2004 Spain DRB, DQB No Associations 27 cases 600 controls - [15]
2010 U.K. DRB1, DQB1 DRB1*1501 
DRB1*07 
53% (32/61) 
10% (6/61) 
30% (57/191) 
29% (56/191) 
0.002 
0.03 
[14]
EditorialDILI is a very rare condition [5], the initial insights into genetic
factors affecting DILI susceptibility do not require the establish-
ment of genetic screening tests that will guide and/or change
clinical practice. Considering the study by Donaldson et al. [14],
shall we perform the HLA mapping in all patients who have to
be treated with co-amoxiclav? Would we prescribe co-amoxiclav
to subjects who have HLA DRB1*15? I suspect that we are moving
in the right direction, but these questions will require more time
to be answered.Conﬂicts of interest
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